ArticleFrontiers in pediatrics2026
Implications of isonicotinylation-associated patterns in NK cells in the pathogenesis of Kawasaki disease: evidence from artificial intelligence-driven multi-omics and clinical validation.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kawasaki disease (KD) is a systemic vasculitis of childhood driven by aberrant immune activation. Natural killer (NK) cell dysregulation plays a critical role, but its upstream molecular mechanisms remain unclear. Isonicotinylation (Kinic), a novel lysine acylation acting as a metabolic sensor, represents an unexplored regulatory layer in KD. Methods: We employed an artificial intelligence (AI)-driven multi-omics framework. Limma differential expression analysis on GSE68004 (KD patient bulk profile) identified Kinic-related differentially expressed genes. Weighted gene co-expression network analysis (WGCNA) and CIBERSORT on GSE18606 (KD patient bulk profile) delineated an NK cell-correlated module. Their intersection defined Kinic- and NK (KN)-related signature, which was used to construct a diagnostic model via an explainable machine learning pipeline on KD patient bulk profiles (GSE73463, GSE73462, and GSE63881). The central hub gene was validated using KD patient single-cell RNA-sequencing (scRNA-seq) data (GSE24757). An AI-based drug screen (DrugReflector) and molecular docking nominated therapeutic candidates. Finally, PPID expression was validated in an independent clinical cohort using q-RT-PCR. Results: We identified a six-gene KN-associated signature that demonstrated excellent diagnostic performance. PPID can be considered upregulated hub gene. Single-cell analysis confirmed predominant PPID expression in NK cells and linked its function to epigenetic modification and inflammatory signaling. Drug screening nominated BRD-K90382497 as a potential PPID-targeting compound. Conclusion: This study unveils a novel KN-associated molecular axis in KD pathogenesis, with PPID as an NK cell-centric hub. This axis provides a promising diagnostic biomarker and identifies a potential therapeutic target, bridging a novel metabolic modification to NK cell dysfunction in KD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.